RET and neoplasm: HM06, another investigational compound, selectively inhibits RET across multiple tumor types in vitro and in vivo, circumvents RET-V804X gatekeeper mutation and RET-G810X resistance mutations (284, 285), and is currently in Phase I/II clinical trials in patients with RET-altered tumors (NCT04683250).